The Epstein-Barr virus (EBV)-associated Although phenotypic analysis of LPDs has suggested similarities with LCLs, based on positive immunohistology for CD23, CD58 (LFA-3), and CD54 (ICAM-1) in three lesions (12), other studies found positive CD23 expression in only five of nine LPD lesions (13), and three lesions were positive for the expression of CD38, a surface antigen associated with plasma-cell formation (13). Furthermore, histopathologic analysis characterizes LPD as polymorphic B-cell immunoblasts with variable degrees ofplasmacytoid features (14) (15) (16) .
nodeficiency mouse model, however, we demonstrate that EBV-infected tumor cells are not LCL-like but are predominantly plasmacytoid and that this phenotype correlates with reduced expression of EBV latent genes. B-cell tumors developed within 3-6 weeks after injection of LCLs into severe combined immunodeficiency mice. The tumors and the injected LCLs were analyzed by flow cytofluorometry for B-ceU differentiation and activation markers and by ribonuclease protection assay for cellular and viral gene expression. No differences in the expression of CD19 and CD21 were observed. However, a decrease in CD23, CD11a (lymphocyte function-associated antigen LFA-1), and CD58 (LFA-3) expression and an increase in CD38 (a plasma-cell-asscted antigen), CD54 (intracellular adhesion molecule ICAM-1), and HLA class I in the tumor cells relative to the LCLs was observed. Two-color flow cytofluorometric analysis showed that the predominant population (>80%) in LCLs was CD23hI/CD38Io and that the major population in LCL-derived tumors was CD2YI/CD38bI. Cell cycle analysis showed that, in contrast to actively cycling LCLs, the majority of tumor cells had exited the cell cycle and were restricted to GO/GI phase. Finally, and most important, a reduction in mRNA for the EBV latent genes EBV nuclear antigen 2 (EBNA2) and latent membrane protein (LMP1) was observed in the tumors.
In humans with latent/persistent Epstein-Barr virus (EBV) infection, outgrowth of infected B cells is thought to be controlled by virus-specific cytotoxic T-cell surveillance; indeed, abrogation of T-cell immunity frequently results in the appearance of the oligoclonal or monoclonal EBVassociated B-cell lymphoproliferative disorders (LPDs) that constitute a major complication in immunocompromised organ allograft recipients (for review, see refs. 1 and 2). The association of EBV with LPDs is based on serologic evidence of EBV infection and the detection of viral DNA and the EBV-encoded antigens EBV nuclear antigen (EBNA) 1, EBNA2, and latent membrane protein (LMP) in the tumors (2, 3) .
Human LPD lesions are considered to be the in vivo equivalent of in vitro lymphoblastoid cell lines (LCLs), which express 10 EBV latent genes: EBNA1, -2, -3A, -3B, and -3C; LMP1 and -2; leader protein; and two untranslated RNA species (EBERs; for review, see ref. 4) . EBNA1 is the only viral gene product required for maintenance of the episomal EBV genome (5, 6) . EBNA2 and LMP1 are effectors of growth transformation (7) (8) (9) . The functions ofthe other genes have not been clearly elucidated. Immortalization of B cells is accompanied by phenotypic changes, including high expression of the B-cell activation antigen CD23 and adhesion molecules CD11a (lymphocyte function-associated antigen LFA-1), CD54 (intracellular adhesion molecule ICAM-1), and CD58 (LFA-3) (10, 11) .
Although phenotypic analysis of LPDs has suggested similarities with LCLs, based on positive immunohistology for CD23, CD58 (LFA-3), and CD54 (ICAM-1) in three lesions (12) , other studies found positive CD23 expression in only five of nine LPD lesions (13) , and three lesions were positive for the expression of CD38, a surface antigen associated with plasma-cell formation (13) . Furthermore, histopathologic analysis characterizes LPD as polymorphic B-cell immunoblasts with variable degrees ofplasmacytoid features (14) (15) (16) .
In this study, we have addressed the question of whether EBV-associated LPDs are mature LCL-like activated B cells or represent a more differentiated plasmacytoid phenotype, by examining patterns of cellular and viral gene expression in EBV-induced LPDs of severe combined immunodeficiency/ human (SCID/hu) chimeric mice, a model that has been shown to be remarkably similar to human posttransplant LPDs (17) (18) (19) . Recent studies on EBV-induced tumor formation in SCID/hu chimeric mice have shown that CD23 and CD20 expression by the tumor cells is greatly reduced relative to donor-matched LCLs (20, 21) and that tumor cells have a plasmacytoid morphology (17, 18) . We injected LCLs into SCID mice and compared the resultant tumor cells to the input LCL. Analysis of LCL-derived tumors, rather than tumors arising in SCID mice engrafted with human peripheral blood (17, 18, 20) (24) and the data were analyzed with LYSIS ii software (Becton Dickinson).
Cell Cycle Analysis. LCLs and tumor cells were stained with acridine orange (Polysciences) and were analyzed with the FACS IV exactly as described (24) . The RNase Protection Assay. RNA was extracted from tumor cells or LCLs by using the one-step method of Chomczynski and Sacchi (29) . Antisense RNA, generated from EcoRIlinearized templates, was synthesized with T7 polymerase, the Riboprobe Gemini core system (Promega), and [32P]UTP (3000 Ci/mmol; 1 Ci = 37 GBq; Amersham) as the labeled nucleotide. The RNA from 1.5 x 106 cells was hybridized with a multiple probe set containing antisense RNA probes specific for CD23, rpL32, EBNA2, and LMP1. Hybridization reactions, RNase treatment, and isolation of protected RNA-RNA duplexes were done as essentially described by Melton et al. (30) with the exception of using only RNase T1. Final samples were electrophoresed in 5% polyacrylamide/8 M urea gels and visualized by autoradiography. Densitometric analysis of autoradiograms was done using an Ultroscan XL densitometer (Pharmacia LKB).
ELISA. Sandwich ELISA was done to detect immunoglobulin in serum and in culture supernatants. Microwell plates were coated (100 ,ul per well) with the capture antibody (goat anti-human A, y, and a; Zymed Laboratories) diluted to 1 ,gg/ml. Serum from mice taken at the time of sacrifice or supernatant from a 48-h culture of 1 x 106 cells was added at various dilutions. The standard was a pool of human IgM, IgG, and IgA myeloma proteins (provided by H. Spiegelberg, University of California, San Diego, La Jolla, CA). The detecting antibody was alkaline phosphatase-conjugated goat anti-human li, a, and y (Zymed Laboratories). The reaction was terminated by addition of 0.3 M NaOH and absorbance at 410 nm was measured (Dynatech model MR600 microplate reader).
RESULTS
By transferring LCLs into SCID mice, we were able to assess phenotypic changes associated with tumor formation by a well-characterized population of rapidly dividing EBVinfected cells. Five LCLs derived by in vitro transformation of mononuclear cells from five donors (EW, TL, LG, JR, and KR) were analyzed to determine whether the results were consistent for different LCLs or specific for a given LCL. Each LCL was transferred into at least four mice. All mice developed tumors. In addition, one cell line, JR, gave rise to both ascites and solid tumor masses. However, no phenotypic differences were observed between ascites and solid tumors. The length of time to debilitating tumor development was characteristic for each LCL and ranged from 18 days after injection (JR) to 38 days after injection (LG).
Morphologic examination of the tumors revealed immunoblastic lymphomas with a predominance of plasmacytoid cells (small nucleus, clock-like dispersed chromatin, large cytoplasm, and a single prominent nucleolus) and variable degrees of necrosis, similar to previous observations (17) . This contrasts with the lymphoblastoid morphology of LCLs (small cell volume, high nucleus/cytoplasm ratio, and multiple prominent nucleoli) (data not shown). A high level of serum immunoglobulin was found in all mice at the time of sacrifice (9-31 mg/ml). This contrasts with the low level of immunoglobulin detected in 24-h supernatants from cultured LCLs (9-17 ,g per ml per 106 cells). (21), we analyzed the expression of the following cell surface markers: HLA class I, CD19, CD21, CD23, CD38, CD11a (LFA-1), CD54 (ICAM-1), and CD58 (LFA-3). CD19 and CD21 are present through pre-B-cell and mature B-cell ontogeny (31) . CD23 is expressed on EBV-infected or mitogen-stimulated B cells, but not on mature plasma cells (31, 32) . CD38 is found only on pre-B cells and plasma cells, but not on activated B cells (31, 33) . The adhesion molecules CD11a and CD58 are expressed during most stages of B-cell differentiation with the exception that expression decreases in plasma cells (34) . Expression of CD54 is B-cell-lineage-specific and is only found on mature B cells and plasma cells (35) . A representative FCF analysis of LG.LCL and matched tumor cells is shown in Fig. 1 . Table  1 is a summary of the mean fluorescence intensities for analyzed pairs of four LCLs and tumor cells.
Clear phenotypic differences between the LCLs and matched tumor cells were observed. The expression ofCD23, CD11a, and CD58 decreased in the tumor cells relative to the LCLs. In contrast, CD38 expression increased in the tumor cells relative to the LCLs. Surprisingly, the levels of HLA class I and CD54 (ICAM-1) were also higher in the tumor cells relative to the LCLs. The cell surface expression ofCD19 and CD21 when calculated by the mean fluorescence intensities do not show statistically significant changes. The phenotype of the tumor cells is consistent with a plasma-cell phenotype. Reduced tumor-cell expression of CD11a, CD23, and CD58 was not a consequence of collagenase digestion of tumors, as collagenase treatment of control LCLs had no effect on expression (data not shown).
The B-cell markers CD23 and CD38 can be used to distinguish activated B cells from mature plasma cells. We performed a two-color FCF analysis to evaluate the coexpression of CD23 and CD38 by the LCLs and the matching tumor cells. The resulting contour plots (Fig. 2 ) reveal distinct differences between the two cell types. Whereas the predominant population (>80%) of LCLs expressed high levels of CD23 (CD23hi) and low levels of CD38 (CD3810), the major population (>80%) of tumor cells expressed the recip- protection assay was done to compare tumor cells and LCLs for levels of transcripts for CD23, EBNA2, LMPI, and a housekeeping gene, rpL32. RNA, extracted from equivalent numbers of cells, was used for hybridization to antisense probes to determine the amount of mRNA per cell. The results of a representative assay are shown in Fig. 4 and the quantitative analysis of the data from all experiments is shown in Fig. 5 . The levels of all measured transcripts were decreased in the tumor cells relative to the LCLs. The EBV latent genes LMP1 and EBNA2 have reduced expression in the tumor cells, with a mean 5-fold decrease measured (Fig. 5) . The reduced expression was consistently observed in all mice as seen in Fig. 4 , LCL tumors 1, 2, and 3. Consistent with the decrease in surface density of CD23 measured by flow cytometry, CD23 mRNA levels were 9-fold lower in tumor cells relative to the LCLs. Interestingly, rpL32 gene expression was also decreased in the tumor cells relative to the LCLs (3-fold), thus, suggesting that overall gene expression is reduced in tumor cells. If the densitometry analyses of EBNA2, LMP1, and CD23 are normalized to rpL32, the levels of EBNA2, LMP1, and CD23 RNAs were still significantly reduced in tumor cells relative to LCLs (2-fold for EBNA2 and LMP1 and 4-fold for CD23). In addition, when hybridization was based on total RNA rather than cell number, these differences were still observed (data not shown). The decrease in measured transcripts is not due to cell death, as only cell samples with >95% viability were used for RNA extraction. associated or iatrogenic immunosuppression and compromised EBV-specific T-cell responses, most notably posttransplant patients. Human LPDs are thought to approximate in vitro-transformed LCLs (12, 37) but commonly exhibit features of plasmacytoid differentiation (13) (14) (15) (16) . In this study on the SCID/hu mouse model of human LPD, we demonstrate that EBV-infected tumor cells are predominantly plasmacytoid rather than LCL-like. This assertion is based on observed changes in cell morphology, the presence of plasma-cell-associated surface markers, increased levels of immunoglobulin secretion, and decreased proliferative activity. These changes were not unique to a given LCL since they were consistent for all lines analyzed. We also make the critical observation that plasmacytoid differentiation is associated with reduced expression of the EBV latent genes EBNA2 and LMP.
Our results suggest that EBV-immortalized cells terminally differentiate in an in vivo environment. This contrasts with the prevailing theory that EBV "fixes" B cells at the lymphoblastoid stage of EBV differentiation (38) , which is characterized by the high level expression of the B-cell activation antigens and adhesion molecules (11) and by continuous proliferation in culture (39) . Our data do not distinguish whether the plasma-like cells in the tumors arose from the outgrowth of a phenotypically different subpopulation of cells in the LCL or from the conversion of the LCL to a differentiated phenotype. B-cell phenotype heterogeneity, characterized by the expression of cytoplasmic immunoglobulin (40) and PC1 [a plasma cell antigen (41) ], has been observed in LCLs, but only in a minority ofthe cells. The low proliferation rate ofthe tumor cells and apparent exit from the cell cycle suggest that entrance into the terminal differentiation pathway eliminates the capacity for self-renewal and argues that the lymphoblastoid cell type in the LCL converts to the plasma cell phenotype in the tumor. This could also be occurring in vitro but passage of EBV-transformed cells in culture would select for actively dividing lymphoblastoid cells. Alternatively, conversion to a terminally differentiated phenotype could be due to the release of human cytokines, such as interleukin 6, in the microenvironment ofthe tumors.
The terminally differentiated phenotype of the tumors correlates with a reduction in the expression of the EBV latent genes EBNA2 and LMP1. Picchio et al. (20) also noted a reduction in EBNA2 expression in EBV-induced tumors in SCID mice relative to LCLs. However, they did not observe a similar decrease in the levels of LMP1. Their data was based on a less-sensitive Western blot analysis, which could explain the difference in results. EBNA2 and LMP1 were also not detected in several samples of human LPDs, based on Western blot analysis (J. McKnight, personal communication), suggesting that these observations are not unique to the SCID mouse model.
We show that CD23 expression is decreased in the tumors at the level of cell surface expression and mRNA accumulation. EBNA2 expression has been shown to transcriptionally upregulate CD23 expression (42) . This would suggest that the decrease in CD23 we observed is caused by the reduction in EBNA2 expression. Alternatively, reduced CD23 and EBNA2 may be independently related to B-cell differentiation, as the CD2310/CD38hi phenotype has been identified by FCF analysis of normal human plasma cells (43) . Interestingly, expression of LMP1 has been correlated with an increased expression of CD11a, CD54, and CD58 after LMP gene transfer into EBV-negative Burkitt lymphoma cells (44) . However, in association with reduced LMP1 in the tumors, we observed a decrease in expression of CD1la and CD58, but not CD54, suggesting that expression of adhesion molecules is also independently regulated and related to differentiation.
The tumors from EBV-induced LPD in SCID mice have been shown to be remarkably similar to human LPD (17, 19) . In this study, we clearly show SCID tumors differ phenotypically from in vitro-transformed LCLs. Ofparticular note, the differentiation-associated reduction in EBV latent gene expression may play a role in the pathogenesis of LPD and underscores the importance of in vivo analysis of EBVinfected B cells.
